Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Low incidence of new biochemical and clinical hypogonadism following hypofractionated stereotactic body radiation therapy (SBRT) monotherapy for low- to intermediate-risk prostate cancer. | Oermann et al. Journal of Hematology Oncology 2011 4 12 http content 4 1 12 JOURNAL OF HEMATOLOGY ONCOLOGY RESEARCH Open Access Low incidence of new biochemical and clinical hypogonadism following hypofractionated stereotactic body radiation therapy SBRT monotherapy for low- to intermediate-risk prostate cancer 1 1 1 1 1 1 1 1 Eric K Oermann Simeng Suy Heather N Hanscom Joy S Kim Sue Lei Xia Yu Guowei Zhang Brook Ennis 4 1 2 11 2 JoyAnn P Rohan Nathaniel Piel Benjamin A Sherer Devin Borum Viola J Chen Gerald P Batipps 2 2 2 2 2 Nicholas L Constantinople Stephen W Dejter Gaurav Bandi John Pahira Kevin G McGeagh Lucile Adams-Campbell4 Reena Jha3 Nancy A Dawson4 Brian T Collins1 Anatoly Dritschilo1 John H Lynch2 and Sean P Collins1 Abstract Background The CyberKnife is an appealing delivery system for hypofractionated stereotactic body radiation therapy SBRT because of its ability to deliver highly conformal radiation therapy to moving targets. This conformity is achieved via 100s of non-coplanar radiation beams which could potentially increase transitory testicular irradiation and result in post-therapy hypogonadism. We report on our early experience with CyberKnife SBRT for low- to intermediate-risk prostate cancer patients and assess the rate of inducing biochemical and clinical hypogonadism. Methods Twenty-six patients were treated with hypofractionated SBRT to a dose of Gy in 5 fractions. All patients had histologically confirmed low- to intermediate-risk prostate adenocarcinoma clinical stage T2b Gleason score 7 PSA 20 ng ml . PSA and total testosterone levels were obtained pre-treatment 1 month posttreatment and every 3 months thereafter for 1 year. Biochemical hypogonadism was defined as a total serum testosterone level below 8 nmol L. Urinary and gastrointestinal toxicity was assessed using Common Toxicity Criteria v3 quality of life was assessed using the American Urological Association Symptom Score Sexual Health Inventory for Men .
